Skip to content

Trial · Interventional

CompletedPhase 1Registry data

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

NCTNCT07619443 (opens ClinicalTrials.gov in a new tab)Other id7262-003Other idMK-7262-003
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 1
Enrollment
30 participants (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Design
Randomized · Open label (no masking)
Countries
1 country

United States

Start
1 Jul 2026
Primary completion
5 Sept 2026
Completion
22 Sept 2026
First posted
2 Jun 2026
Last update posted
25 Sept 2026
Conditions
Healthy

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20262027
  1. Ph 1

    A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

    NCT07619443

    1 Jul 2026 to 22 Sept 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Interventions

  • MK-7262Drug
  • EnlicitideDrug

Arms3

  • Experimental

    MK-7262

    Participants will receive MK-7262 orally.

  • Experimental

    Enlicitide

    Participants will receive enlicitide orally.

  • Experimental

    MK-7262 plus Enlicitide

    Participants will receive MK-7262 and enlicitide orally.

Primary outcomes4

Outcomes the sponsor listed as primary.

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 8 days)

    Registry description

    Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.

  2. AUC0-inf of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.

  3. Maximum Plasma Concentration (Cmax) of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.

  4. Cmax of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.

Secondary outcomes(14)

  1. Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 24 hours post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the AUC0-24 of MK-7262.

  2. Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the AUC0-last of MK-7262.

  3. Time to Maximum Plasma Concentration (Tmax) of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the Tmax of MK-7262.

  4. Apparent Terminal Half-life (t1/2) of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the t1/2 of MK-7262.

  5. Apparent Clearance (CL/F) of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the CL/F of MK-7262.

  6. Apparent Volume of Distribution During Terminal Phase (Vz/F)of MK-7262

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the Vz/F of MK-7262.

  7. AUC0-24 of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 24 hours post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the AUC0-24 of enlicitide.

  8. AUC0-last of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the AUC0-last of enlicitide.

  9. Tmax of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the Tmax of enlicitide.

  10. t1/2 of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the t1/2 of enlicitide.

  11. CL/F of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the CL/F of enlicitide.

  12. Vz/F of Enlicitide

    Time frame · Predose and at designated time points post-dose (up to 8 days post-dose)

    Registry description

    Blood samples will be collected at multiple time points to estimate the Vz/F of enlicitide.

  13. Number of Participants Who Experience One or More Adverse Events (AEs)

    Time frame · Up to approximately 8 weeks

    Registry description

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

  14. Number of Participants Who Discontinue Study Due to an AE

    Time frame · Up to approximately 6 weeks

    Registry description

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 19 Years up to 55 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health before randomization * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history or presence of clinically significant medical or psychiatric condition or disease * Has a history of cancer

PepBank is a research reference. Talk to a doctor before you use any peptide.